Rchr
J-GLOBAL ID:201901011621618269   Update date: Nov. 22, 2024

Mototsugu Shimokawa

Mototsugu Shimokawa
Affiliation and department:
Other affiliations (1):
Homepage URL  (1): http://biostat.med.yamaguchi-u.ac.jp/introduction.html
Research field  (1): Statistical science
Research theme for competitive and other funds  (2):
  • 2020 - 2025 免疫チェックポイント阻害治療最適化のためのマイクロサテライト不安定性多様性の解明
  • 2011 - 2012 A Historical Study of the Department of Medicine,Kyushu University - A New Bioethics & Medical Ethics of Educational Research -
Papers (290):
  • Kotaro Nomura, Kazuki Takada, Fumihiko Kinoshita, Satoshi Muto, Taichi Matsubara, Yasunobu Kouki, Shinya Katsumata, Akira Hamada, Naoki Haratake, Kosuke Fujino, et al. Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study). International journal of cancer. 2024
  • Asato Hashinokuchi, Shinkichi Takamori, Masafumi Yamaguchi, Saito Shunichi, Kyoto Matsudo, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Mototsugu Shimokawa, et al. Prognostic significance of preoperative creatine kinase in resected thymic epithelial tumors. Journal of thoracic disease. 2024. 16. 7. 4186-4194
  • Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel. Scientific reports. 2024. 14. 1. 16906-16906
  • Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, et al. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. Lung cancer (Amsterdam, Netherlands). 2024. 193. 107852-107852
  • Kaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa, Hidehito Horinouchi, Masahiro Morise, Kadoaki Ohashi, Haruyasu Murakami, Miyako Satouchi, Jun Sakakibara-Konishi, Seiji Yano, et al. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study. International journal of clinical oncology. 2024
more...
MISC (38):
  • Shingo Noura, Ryo Inada, Hitoshi Ojima, Takeshi Nagasaka, Hiroaki Tanioka, Yoshinori Munemoto, Yasuhiro Shimada, Keiichiro Ishibashi, Yoshiaki Shindo, Mototsugu Shimokawa, et al. QoL analysis: A randomized phase 3 study of sequential versus combination treatment in firstline chemotherapy for metastatic colorectal cancer-The C-cubed study. JOURNAL OF CLINICAL ONCOLOGY. 2022. 40. 4
  • Meiko Nishimura, Takahiro Kogawa, Yuko Akaishi, Misato Ogata, Jun Masuda, Mitsuo Terada, Hitomi Sakai, Kazuki Nozawa, Sasagu Kurozumi, Takamichi Yokoe, et al. Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients. CANCER RESEARCH. 2022. 82. 4
  • 阪本智宏, 松原太一, 高濱隆幸, 横山俊秀, 中村敦, 時任高章, 岡本龍郎, 赤松弘朗, 沖昌英, 佐藤悠城, et al. 進行・再発非小細胞肺癌のバイオマーカー検査と標的治療に関する実態調査プロジェクト:WJOG15421L(REVEAL). 日本肺癌学会学術集会号. 2022. 63rd (CD-ROM)
  • 橋本幸輝, 林稔展, 下川元継, 松井礼子, 藤堂真紀, 玉木慎也, 原田知彦, 佐野元彦, 小池恭正, 藤田行代志, et al. Multicenter survey analyzing the use of olanzapine for breakthrough chemotherapy-induced nausea and vomiting. 日本臨床腫瘍学会学術集会(CD-ROM). 2022. 19th
  • Kazuki Takada, Shinkichi Takamori, Naoko Miura, Yasunori Shikada, Mototsugu Shimokawa. Reasons to Consider the COVID-19 Vaccination Status of Patients With Cancer When Analyzing Their COVID-19 Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021. 39. 35. 3996-3996
more...
Books (1):
  • SASによるデータ解析入門
    東京大学出版会 2011 ISBN:9784130640855
Education (2):
  • 2014 - 九州大学大学院 医学系学府保健学専攻後期博士課程
  • 2000 - 東京理科大学大学院 工学研究科経営工学専攻修士課程
Professional career (1):
  • 保健学博士 (九州大学)
Work history (3):
  • 2019/04 - 現在 国立大学法人山口大学大学院医学系研究科 医学統計学分野 教授
  • 2012 - 2019 独立行政法人国立病院機構九州がんセンター 臨床研究センター 腫瘍統計学研究室長
  • 2009 - 2012 九州大学病院 高度先端医療センター (現,ARO次世代医療センター) 特任助教
Committee career (11):
  • 公益財団法人がん研究会 有明病院 先端医療開発センター 統計アドバイザー
  • 国立病院機構九州医療センター 統計アドバイザー
  • 九州大学 特定認定再生医療等委員会 委員
  • 日本がんサポーティブケア学会 評議員,ガイドライン委員
  • 西日本がん研究機構(WJOG) 統計アドバイザー
Show all
Association Membership(s) (7):
American Society of Clinical Oncology ,  European Society for Medical Oncology ,  International Biometric Society ,  日本計量生物学会 ,  日本臨床腫瘍学会 ,  日本臨床試験学会 ,  日本がんサポーティブケア学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page